Jounce Therapeutics (JNCE) 10-Q2020 Q1 Quarterly report

Filed: 6 May 20, 1:56pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accessibility, affirmed, agonist, Aid, aim, ATM, attain, average, avoid, back, baseline, Brexit, called, catastrophic, chain, China, Cloud, concurrent, confidence, conjugate, contact, Corrupt, Cowen, currency, deplete, depleting, depreciation, difficulty, distancing, docetaxel, electorate, enumerated, EU, expedited, FFCR, flat, forthcoming, forward, foster, framework, gene, geographic, goodwill, Hedging, hosting, immunosuppressive, indefinitely, Inflammation, intraperiod, job, left, lessen, light, local, Minister, mitigate, modest, modification, NSCLC, offshore, opposition, outbreak, pace, pandemic, paused, payroll, preferentially, protracted, question, randomized, reconsideration, regime, Relief, remanded, remeasurement, repatriated, retroactively, retrospectively, RNA, shipping, Signature, software, spread, statistical, strain, Subtopic, taxable, taxation, temporarily, threshold, TISvopra, top, travel, UK, unavailable, unconstitutional, unfavorable, unfold, uninsured, Union, worsening, Wuhan, Xencor

Removed: American, amortizing, applying, borrowing, classification, close, comparative, consecutive, consummated, curve, customary, deposit, differentiate, discount, discounted, durable, expedient, feet, harnessing, hindsight, implicit, inappropriate, incremental, insured, investigator, landlord, Leasehold, leasing, legacy, lessee, Likewise, line, modified, nivolumab, Nonemployee, nonlease, occupy, oncology, opening, pembrolizumab, practical, present, range, ratably, rating, RECIST, remained, rent, rental, repurchase, retained, RSA, separating, shorter, simplify, space, square, summary, synthetic, tenant, utilized, Xenor, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated JNCE transcripts

JNCE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Jounce Therapeutics, Inc. (the “Company”) for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her or his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Date: May 6, 2020	By:	/s/ Richard Murray
		Richard Murray, Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: May 6, 2020	By:	/s/ Kim C. Drapkin
		Kim C. Drapkin
		Treasurer and Chief Financial Officer
		(Principal Financial and Accounting Officer)